Drug intelligence / Profile preview

ONCR-201

Development stage: Preclinical
Lead developer: OncoResponse
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ONCR-201 is a fully human monoclonal antibody that targets epithelial membrane protein 2 (EMP2), an oncoprotein. EMP2 is overexpressed in aggressive cancers such as triple-negative breast cancer, ovarian cancer, endometrial cancer, and glioblastoma. Originally developed by Paganini Biopharma, ONCR-201 was acquired by OncoResponse to expand its oncology pipeline with a preclinical candidate. The drug was placed on an IND-track for first-in-human studies planned for 2019, aiming to treat these aggressive cancers by targeting EMP2.

Targets

EMP2 (Epithelial membrane protein 2)

Beyond the preview

Go deeper on ONCR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCR-201.

Explore the full profile